Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stronger Focus On Targeting Corporate Executives In DoJ Manual Update

This article was originally published in The Tan Sheet

Executive Summary

The updated US Attorney’s Manual instructs government lawyers to focus on individuals from the launch of civil or criminal investigations into a company, and not to consider individual’s ability to pay a judgment in deciding whether to pursue charges.

You may also be interested in...



Protecting Against Individual Prosecutions: Execs Remain A Focus, But There Are Ways To Reduce Risks

As the US Justice Department continues its focus on individual liability in device industry enforcement, it’s more important than ever that manufacturers bring executives in early on problems to limit liability.

Supplement Sector Regulatory Milestones: Senators' Enforcement Push, GNC Supply Chain Guidelines

Former FDA OCI Director George Karavetsos says GNC's supply chain guidelines for its vendors is the industry standard, while Sens. Hatch and Heinrich exceeded all standards by recommending DoJ get tougher on firms violating FDA supplement product regulations,

Park Prosecutions Are Expected To Continue: Here Are Some Tips

The US Department of Justice is expected to continue ramping up its scrutiny of individuals under what’s called the Park Doctrine, attorneys say. The best defense may be taking awareness to the board of directors, they claim.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel